IDH1 and neoplasm: For instance, the granulocyte colony-stimulating factor secreted by mutated IDH1 glioma could enhance the efficacy of immunotherapy for patients with LGG by reprogramming the tumor microenvironment and promoting the generation of non-immunosuppressive myeloid cells (32).